Stay updated on Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    7 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2 to the history and removed Revision: v3.5.0.
    Difference
    0.0%
    Check dated 2026-04-16T10:58:37.000Z thumbnail image
  3. Check
    14 days ago
    No Change Detected
  4. Check
    36 days ago
    Change Detected
    Summary
    New revision entry v3.5.0 added to the history. The v3.4.3 entry was removed.
    Difference
    0.0%
    Check dated 2026-03-18T18:00:40.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    Footer revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-11T14:57:46.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    The trial status is updated to Terminated with primary results showing no benefit from canakinumab. The previous Active, not recruiting status has been removed.
    Difference
    0.2%
    Check dated 2026-03-04T09:28:00.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The latest version adds a Contacts/Locations section and a Study Status update to the record. These additions improve access to study contact information and the current recruitment status.
    Difference
    0.5%
    Check dated 2026-02-11T10:01:18.000Z thumbnail image
  8. Check
    78 days ago
    Change Detected
    Summary
    Added a site-wide funding/operating status notice and Revision: v3.4.1; removed Revision: v3.4.0.
    Difference
    0.3%
    Check dated 2026-02-04T07:40:00.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page.